Shares of Neuland Laboratories plummeted 8% on December 12, 2024, following a block deal worth ₹780.30 crore on the exchanges. Reports suggest that Smallcap World Fund, which previously held a 3.77% stake in the company, may have offloaded its shares in the transaction.

• Around 4.9 lakh shares (or 3.8% of the company) were traded at an average price of ₹15,900 per share—representing a 6% discount from the previous day’s closing price.
• By 9:53 AM, Neuland Labs shares were trading at ₹16,104 on the NSE, reflecting heightened volatility and selling pressure.

Spike in Trading Volumes

The block deal triggered a surge in trading activity, with over 7 lakh shares changing hands—well above the one-month daily average of 52,000 shares, indicating strong interest in the stock.

Possible Exit of Smallcap World Fund

Reports from ET-Now suggested that Smallcap World Fund had been planning to sell its 3.8% stake in Neuland Labs, aiming to raise approximately ₹747 crore. If confirmed, this block deal likely marks the fund’s exit from Neuland Laboratories.

Stock Decline and Recent Sentiment

This development comes amid a broader 10% correction in Neuland Labs’ stock over the past week, driven by several factors:

1. Uncertainty Surrounding the US Biosecure Act:

   • The US Biosecure Act, a potential catalyst for accelerating the China+1 strategy among US pharmaceutical innovators, failed to gain approval.
   • The Act was excluded from a key defense bill, signaling a potential easing of US restrictions on Chinese biotech, which dampened sentiment for Indian CDMO (Contract Development and Manufacturing Organization) players like Neuland Labs.

2. Sector-Wide Concerns:

   • The exclusion of the Biosecure Act from the defense bill reduced optimism for increased outsourcing to Indian pharmaceutical companies, which could have benefited from tighter US scrutiny of Chinese manufacturers.

Neuland Labs: Company Profile and Market Position

Founded in 1984, Neuland Laboratories specializes in Active Pharmaceutical Ingredients (APIs) and is a prominent player in the CDMO space. The company has been a key beneficiary of the China+1 strategy, which encourages global firms to diversify their supply chains away from China.

Despite the current headwinds, Neuland’s strategic focus on innovation and its established client base in regulated markets provide a robust foundation for long-term growth.

Impact of Block Deal and Broader Outlook

The block deal raises questions about institutional confidence, as Smallcap World Fund was a significant shareholder. While the immediate reaction has been negative, market watchers will look for clarity on:

1. The buyer of the block deal and their potential strategic interest.
2. Neuland Labs’ ability to navigate macroeconomic uncertainties and sustain growth.

Conclusion

The 8% plunge in Neuland Labs’ shares following the block deal reflects near-term investor concerns. While Smallcap World Fund’s likely exit adds to the pressure, the broader uncertainty surrounding the US Biosecure Act has compounded the stock’s challenges.

Going forward, investors will keep a close eye on developments in the CDMO sector, as well as the company’s ability to capitalize on global pharmaceutical trends.

The Upcoming IPOs in this week and coming weeks are Hamps Bio, NACDAC Infrastructure, Transrail Lighting, Rosmerta Digital and Avanse Financial.

The Current active IPO is and Yash Highvoltage, Inventurus Knowledge, Sai Life Sciences, Mobikwik, Vishal Mega Mart, Supreme Facility, Purple United, Jungle Camps and Toss The Coin.